



# Emerging Biosensing Technologies for Neuroinflammatory and Neurodegenerative Disease Diagnostics

Catarina M. Abreu<sup>1,2†</sup>, Ricardo Soares-dos-Reis<sup>3,4,5†</sup>, Pedro N. Melo<sup>6,7</sup>, João B. Relvas<sup>7</sup>, Joana Guimarães<sup>3,4,8</sup>, Maria José Sá<sup>3,9,10</sup>, Andrea P. Cruz<sup>1\*</sup> and Inês Mendes Pinto<sup>1\*</sup>

<sup>1</sup> International Iberian Nanotechnology Laboratory, Braga, Portugal, <sup>2</sup> Medical School, Swansea University, Swansea, United Kingdom, <sup>3</sup> Neurology Department, Centro Hospitalar de São João, Porto, Portugal, <sup>4</sup> Department of Clinical Neurosciences and Mental Health, Faculdade de Medicina, Universidade do Porto, Porto, Portugal, <sup>5</sup> Department of Biomedicine, Faculdade de Medicina, Universidade do Porto, Porto, Portugal, <sup>6</sup> Graduate Programme in Areas of Basic and Applied Biology, Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal, <sup>7</sup> Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Porto, Portugal, <sup>8</sup> Center for Drug Discovery and Innovative Medicines (MedInUP), Universidade do Porto, Porto, Portugal, <sup>9</sup> Energy, Environment and Health Research Unit (FP-ENAS), University Fernando Pessoa, Porto, Portugal, <sup>10</sup> Faculty of Health Sciences, University Fernando Pessoa, Porto, Portugal

## OPEN ACCESS

### Edited by:

Nashat Abumaria,  
Fudan University, China

### Reviewed by:

Juan Pablo De Rivero Vaccari,  
University of Miami, United States  
Maciej Maurycy Lalowski,  
University of Helsinki, Finland

### \*Correspondence:

Andrea P. Cruz  
andrea.cruz@inl.int  
Inês Mendes Pinto  
ines.m.pinto@inl.int

†These authors have contributed  
equally to this work.

**Received:** 22 February 2018

**Accepted:** 30 April 2018

**Published:** 16 May 2018

### Citation:

Abreu CM, Soares-dos-Reis R,  
Melo PN, Relvas JB, Guimarães J,  
Sá MJ, Cruz AP and Mendes Pinto I  
(2018) Emerging Biosensing  
Technologies for Neuroinflammatory  
and Neurodegenerative Disease  
Diagnostics.

Front. Mol. Neurosci. 11:164.  
doi: 10.3389/fnmol.2018.00164

Neuroinflammation plays a critical role in the onset and progression of many neurological disorders, including Multiple Sclerosis, Alzheimer's and Parkinson's diseases. In these clinical conditions the underlying neuroinflammatory processes are significantly heterogeneous. Nevertheless, a common link is the chronic activation of innate immune responses and imbalanced secretion of pro and anti-inflammatory mediators. In light of this, the discovery of robust biomarkers is crucial for screening, early diagnosis, and monitoring of neurological diseases. However, the difficulty to investigate biochemical processes directly in the central nervous system (CNS) is challenging. In recent years, biomarkers of CNS inflammatory responses have been identified in different body fluids, such as blood, cerebrospinal fluid, and tears. In addition, progress in micro and nanotechnology has enabled the development of biosensing platforms capable of detecting in real-time, multiple biomarkers in clinically relevant samples. Biosensing technologies are approaching maturity where they will become deployed in community settings, at which point screening programs and personalized medicine will become a reality. In this multidisciplinary review, our goal is to highlight both clinical and recent technological advances toward the development of multiplex-based solutions for effective neuroinflammatory and neurodegenerative disease diagnostics and monitoring.

**Keywords:** neuroinflammation, biomarkers, Alzheimer's disease, Parkinson's disease, Multiple Sclerosis, biosensors, multiplex

## NEURODEGENERATION AND INFLAMMATION: A CLINICAL AND MOLECULAR PERSPECTIVE

Neurological disorders account for an increasing number of disability-adjusted life-years worldwide, especially in high-income countries. Alzheimer's disease, Parkinson's disease and Multiple Sclerosis are the most prevalent causes of neurological disability (Hay et al., 2017). The three different conditions share features of neurodegeneration and neuroinflammation and their diagnosis rely mainly on clinical examination, complemented by imaging and biomarker analysis (Table 1) (Poewe et al., 2017; Lane et al., 2018; Reich et al., 2018).

Alzheimer's disease (AD) is a neurodegenerative disorder primarily affecting neocortical regions and characterized by progressive episodic memory loss leading to significant behavioral changes (McDonald et al., 2009; Lane et al., 2018). Definite AD diagnosis is histopathological, while diagnosis of probable/possible AD dementia is only made by clinical assessment. Diagnostic accuracy can be enhanced by further findings of low amyloid-beta ( $A\beta$ ) levels and an increase in the total or phosphorylated tau protein in cerebrospinal fluid (CSF) (McKhann et al., 2011). Furthermore, positron emitting tomography (PET) showing increased amyloid deposition or decreased fluorodeoxyglucose uptake in the temporoparietal cortex also represent acceptable evidence of the AD pathophysiological process (McKhann et al., 2011). Overall, AD pathology has been classically associated to the presence of amyloid plaques (neuritic plaques) and hyperphosphorylated tau aggregates (neurofibrillary tangles, NFTs) in the brain, which titrates the corresponding levels in the CSF. Amyloid plaques are believed to arise from an imbalance between  $A\beta_{1-42}$  production [via  $\gamma$  and  $\beta$ -secretase 1 (BACE1) cleavage of amyloid precursor protein] and its clearance, leading to the formation of toxic oligomers ( $A\beta O$ ), subsequent synaptic dysfunction and neuronal cell death (Lane et al., 2018). In dominant inherited forms of AD (including mutations in  $\gamma$ -secretase subunits, *PSEN1* and *PSEN2*) the formation of amyloid plaques is promoted by an increased production of  $A\beta_{1-42}$ , while in sporadic AD it is mainly due to impaired  $A\beta$  clearance (Mawuenyega et al., 2010; Lane et al., 2018). Mutations in genes coding for proteins involved in  $A\beta$  clearance pathways represent risk factors for AD, among these are apolipoprotein E (APOE) and the immune receptors: triggering receptor expressed on myeloid cells 2 (TREM2), cluster of differentiation 33 (CD33), and complement region 1 (CR1). TREM2, CD33, and CR1 are expressed in microglia, the innate immune cells of the central nervous system (CNS) and have been found to be associated with a higher risk of AD (Polvikoski et al., 1995; Bradshaw et al., 2013; Crehan et al., 2013; Grieciuc et al., 2013; Guerreiro et al., 2013; Farfel et al., 2016). Microglia activation can have a neurotoxic role in AD through activation of the complement system (e.g., C1q, C3) and the inflammasome, release of pro-inflammatory mediators [e.g., interleukin-1 (IL-1), IL-6 and tumor necrosis factor  $\alpha$  (TNF $\alpha$ )] and leading to synaptic loss, mitogen-activated protein kinase (MAPK) activation and subsequent NFTs formation (Griffin et al., 2006; Heneka et al., 2013; Dursun et al., 2015; Wang


et al., 2015; Hong et al., 2016; Fonseca et al., 2017; Liddelov et al., 2017). Despite the supporting evidence of the innate immunity pathways in AD pathogenesis, attempts to modulate the inflammatory response in patients with AD have mostly failed at improving cognition and halting disease progression (Bronzuoli et al., 2016; Dansokho and Heneka, 2017; Honig et al., 2018).

Parkinson's disease (PD), the second most common neurodegenerative disorder, is characterized by the early and progressive loss of dopaminergic neurons in the *substantia nigra pars compacta* associated with abnormal  $\alpha$ -synuclein ( $\alpha$ -syn) deposition (Kalia and Lang, 2015). The resulting striatal dopamine deficiency leads to a movement disorder with a clinically recognizable triad of motor symptoms: bradykinesia ("slow movement") together with resting tremor and/or rigidity initially restricted to one limb or hemibody, slowly progressing to affect the rest of the body. However, PD is also associated with pathological changes in other brain regions causing non-motor symptoms (e.g., hyposmia, dysautonomia, sleep, and psychiatric/cognitive disorders) that add to overall disability and can precede motor dysfunction (Kalia and Lang, 2015). These likely reflects the distribution of  $\alpha$ -syn aggregates to other regions of the nervous system (Postuma et al., 2015; Poewe et al., 2017). PD diagnosis is exclusively clinical. However, ancillary tests include metaiodobenzylguanidine (MIBG) scintigraphy demonstrating cardiac sympathetic denervation, olfactory function testing and pre-synaptic dopamine (DA) receptor  $^{123}I$ -ioflupane single-photon emission computed tomography (SPECT) imaging. Biomarker analysis, including  $\alpha$ -syn, in serum or CSF, is not performed in standard clinical practice (Postuma et al., 2015). Nevertheless,  $\alpha$ -syn aggregates in specific brain regions are recognized neuropathological hallmarks of PD. In fact,  $\alpha$ -syn mutation is responsible for heritable forms of PD (Poewe et al., 2017). Other genes identified in inherited PD and corresponding proteins, include *PARK7* (deglycase DJ-1), *GBA* (glucocerebrosidase), *PRKN* (parkin), and *LRRK2* (leucine-rich repeat kinase 2) which are expressed in microglia (Lee et al., 2017). At large, the physiological functions of PD-associated genes in immune cells remain elusive. Nevertheless, it is possible that mutations in those genes can alter their normal microglia functions worsening the progression of inflammation-mediated PD neurodegeneration (Lee et al., 2017). Studies found signs of microglia activation and chronic inflammation in the brains of PD patients (McGeer et al., 1988; Gerhard et al., 2006) and  $\alpha$ -syn aggregates are capable of activating microglia *in vitro* and in mouse models (Brochard et al., 2009). Pro-inflammatory cytokines, such as TNF $\alpha$ , IL-1 $\beta$ , IL-6, IL-2, and IL-10 are increased in *postmortem* brain (Mogi et al., 1994b), CSF (Mogi et al., 1994a), and serum (Dufek et al., 2009; Williams-Gray et al., 2016) of PD patients and may be predictive of disease progression.

Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disorder of the CNS of unknown etiology but with a genetic predisposition and environmental influence (Dendrou et al., 2015; Reich et al., 2018). Initial symptoms are variable and related with the affected area of the CNS (Mowry et al., 2009; Pires et al., 2016). Diagnosis of MS requires clinical or radiological

**TABLE 1** | Biomarkers of neurodegeneration and neuroinflammation in Multiple Sclerosis, Parkinson, and Alzheimer's disease<sup>a</sup>.

Disorder	Biomarker type	Current biomarkers	Inflammatory biomarkers	Neurodegeneration biomarkers	AUC
<b>MS</b>	Clinical	Neurological disability	Relapse	EDSS progression	-
	Imaging	MRI w/gadolinium	<sup>11</sup> C-PK11195 PET (mainly plaques) (Inglesse and Petracca, 2013)	Brain atrophy (MRI); <sup>11</sup> C-flumazenil PET (Inglesse and Petracca, 2013)	-
	Serum	-	TNF $\alpha$ , IL-1 $\beta$ , RANKL, IL-17, PTX3, IL-10 (D'Ambrosio et al., 2015); OPN (Housley et al., 2015)	NfH (Zeiterberg, 2017); NfH (Housley et al., 2015)	NfH (0.663) (Novakova et al., 2017b); IFN $\gamma$ (0.91) (Arelano et al., 2017)
	CSF	Oligoclonal bands; IgG index	CHI3L1 (Novakova et al., 2017a); CXCL13, IL-23, IL-17, CXCL10, TNF $\alpha$ , TGF- $\beta$ (Kothur et al., 2016); CHT1, MCP-1, GFAP (Novakova et al., 2017a); sTREM2 (Zeiterberg, 2017); OPN (Housley et al., 2015)	NfH, NGRN (Novakova et al., 2017a); NfH (Housley et al., 2015); NAA(low) (Teunissen et al., 2015)	NfH (0.774) (Novakova et al., 2017b); CHI3L1 (0.82) (Opsahl et al., 2016); CXCL13 (0.80) (Stilund et al., 2015)
<b>PD</b>	Clinical	Bradykinesia; Rigidity; Resting tremor	-	Disability	-
	Imaging	MIBG scintigraphy; SPECT ( <sup>123</sup> I-iodoflupane)	<sup>11</sup> C-PK11195 PET (midbrain/outamen) (Inglesse and Petracca, 2013)	-	-
	Serum	-	IFN $\gamma$ , IL-1 $\beta$ , IL-2, IL-3, IL-10, MIF, TNF $\alpha$ (Focha et al., 2015); $\alpha$ -syn specific T-cells (Suizer et al., 2017); N-glycated IgG (Russell et al., 2017) MIP-1 $\beta$ , MCP-1, IL-8 (Brockmann et al., 2017)	-	NfH (0.91) (Hansson et al., 2017); IL-8 (0.895), MCP-1 (0.736); MIP-1 $\beta$ (0.767) (Brockmann et al., 2017); N-glycated IgG (0.92) (Russell et al., 2017)
	CSF	-	$\beta$ 2-microglobulin, IL-8, IL-6, TNF $\alpha$ , CHI3L1 (Andersen et al., 2017)	Dopamine (loss), NfH (low) (Andersen et al., 2017)	TNF $\alpha$ (0.658) (Delgado-Alvarado et al., 2017)
<b>AD</b>	Clinical	Progressive episodic memory loss	-	Loss of autonomy	-
	Imaging	PET/PIB; MRI	<sup>11</sup> C-PK11195 PET (temporo-parietal cortex) (Inglesse and Petracca, 2013)	MRI; <sup>11</sup> C-flumazenil PET (Pascual et al., 2012)	-
	Serum	-	CHI3L1 (Olsson et al., 2016); IL-8 (Popp et al., 2017); FGF-1, IL-1 $\beta$ , IL-10, IL-11, IL-18 (Brosseron et al., 2014); IL-3, MCP-1, RANTES, sIL-6R, TGF- $\beta$ 1 (Delaby et al., 2015); sCD40L (Yu et al., 2016)	Total tau (Olsson et al., 2016); NSE (Huyhyn and Mohan, 2017)	IL-8 (0.589), IL-3 (0.549), MCP-1 (0.501), RANTES (0.556), sIL6-R (0.595), TGF- $\beta$ 1 (0.567) (Delaby et al., 2015); sCD40L (0.824) (Yu et al., 2016)
	CSF	A $\beta$ <sub>1-42</sub> ; total tau; p-tau	CHI3L1, MCP-1 (Olsson et al., 2016); IL-15, sFLT-1, sICAM-1 (Popp et al., 2017), MIP-1 $\beta$ , MIP-3 $\beta$ , sIL-6R (Delaby et al., 2015); IL-1 $\beta$ (Hesse et al., 2016)	VILIP-1 (Huyhyn and Mohan, 2017); NGRN (Novakova et al., 2017a); NfH, NSE, HFABP (Olsson et al., 2016)	MCP-1 (0.503), MIP-1 $\beta$ (0.655), MIP-3 $\beta$ (0.727), p-tau (0.946), sIL-6R (0.755), tau (0.942) (Delaby et al., 2015); CHI3L1 (0.75) (Paterson et al., 2016); IL-8 (0.614) (Delaby et al., 2015); IL-1 $\beta$ (0.62) (Hesse et al., 2016)



<sup>a</sup>The table above is not intended as an exhaustive review. Only markers studied in human subjects were included. No animal or ex-vivo data was considered. Only one PET ligand per molecule was considered (e.g., other ligands for TSP0 or amyloid exist). AUC of inflammatory biomarkers indicated when available (values are highly cohort specific and vary according to disease, test sample and quantification method). AD, Alzheimer's Disease; AUC, Area Under Curve; <sup>11</sup>C-PK11195, a TSP0 radioligand reflecting microglial activation; CHI3L1, chitinase-3-like protein 1; CHT1, chitotriosidase; CXCL13, C-X-C motif ligand 13; EDSS, Kurtzke Expanded Disability Status Scale; FGF, fibroblast growth factor; GFAP, glial fibrillary acidic protein; HFABP, Heart fatty acid binding protein; MCP-1, monocyte chemoattractant protein-1; MIBG, metaiodobenzylguanidine; MIP, Macrophage Inflammatory Proteins; MRI, magnetic resonance imaging; MS, Multiple Sclerosis; NAA, N-acetylaspartate; NfH, neurofilament heavy chain protein; NGRN, neurogranin; NSE, neuron-specific enolase; OPN, osteopontin; PD, Parkinson's Disease; PET, Positron Emission Tomography; PIB, Pittsburgh compound B; PTX3, pentraxin 3; RANKL, receptor activator of nuclear factor kappa-B ligand; SPECT, Single-photon emission computed tomography; sFLT-1, soluble fms-related tyrosine kinase 1; sICAM-1, soluble intercellular adhesion molecule 1; sIL-6R, Soluble Interleukin-6 receptor; sTREM2, secreted form of the triggering receptor expressed on myeloid cells 2; TGF- $\beta$ 1, transforming growth factor beta 1; VILIP-1, Visinin-like protein 1.

evidence of lesion dissemination in time and/or space. Magnetic resonance imaging (MRI) is the conventional diagnostic tool, while serum and CSF testing are useful in excluding other pathologies. The presence of CSF-restricted oligoclonal bands (OCBs) supports MS diagnosis, however it is not MS-specific (Thompson et al., 2017). CSF-restricted OCBs can be found in other diseases whose clinical and imaging characteristics differ from MS, such as systemic inflammatory disorders with CNS expression (e.g., Systemic Lupus Erythematosus, Sarcoidosis, and Behçet's disease), CNS infections (e.g., Neurosyphilis, HIV, Neuroborreliosis, Subacute Sclerosing Panencephalitis) and in some hereditary disorders (e.g., Ataxia-telangiectasia and Adrenoleukodystrophy) (Giovannoni, 2014).

In MS lesions, histopathology reveals profound myelin loss, increased inflammatory response, and secondary axonal degeneration. Microglia activation perpetuates the underlying inflammatory response at the demyelinated plaque and at sites remote from the lesion (Dendrou et al., 2015). Microglia-driven production of reactive oxygen and nitrogen species, which stress the neuronal and mitochondrial metabolism, promotes neuronal death (Schuh et al., 2014; Choi et al., 2017; Luo et al., 2017) which leads to the release of cytoskeletal elements into the CSF, such as neurofilaments (NFs). NFs are promising biomarkers for predicting lesion burden, therapeutic response, and disease progression (Zetterberg, 2017).

CNS tissue damage in MS results from an intricate interplay between the immune system, glial cells, and neurons. Although there is ongoing debate regarding MS origin, i.e., the “outside-in” (peripheral immune cell invasion of the CNS) or “inside-out” (CNS-intrinsic initiation of the inflammatory cascade) models (Reich et al., 2018), studies in animal models, and in patient CSF and blood samples have disclosed a critical role for adaptive immunity (auto-reactive T and B cells and autoantibodies) (Reich et al., 2018). Despite the knowledge gap regarding MS initial immunopathogenesis, therapies directed both at T cells and B cells have been effective in reducing relapse rate and disease progression (Pires et al., 2016; Reich et al., 2018).

Although the trigger for inflammation might be specific for each of the diseases mentioned above, evidence suggests that AD, PD, and MS share common cellular and molecular mechanisms for sensing, transducing and amplifying inflammation that results in the production of mediators of inflammation, neurotoxicity and, ultimately, neuronal cell death (Yadav et al., 2015; Guillot-Sestier and Town, 2017). Activation of microglial cells is a key event in such neuroinflammatory processes (Ginhoux and Williams, 2016). Under physiological conditions microglia assume immune surveillance functions but upon tissue damage or infection they change their morphology and transcriptomic profile enabling them to restore tissue homeostasis (Crotti and Ransohoff, 2016). Through pattern recognition receptors, including TREM2, microglial cells recognize environmental cues that instruct them to initiate inflammatory responses by triggering downstream signaling pathways regulating the activity of the transcription factors AP-1 and NF- $\kappa$ B, which in turn control the production and release of inflammatory mediators, such as the cytokines TNF $\alpha$ , IL-1 $\beta$ , IL-6, and IL-8, reactive oxygen and nitrogen species (Ortiz et al.,

2013; Leszek et al., 2016; Labzin et al., 2018). The analysis of inflammatory profile, in association with classical disease-specific biomarkers could potentially increase diagnostic and prognostic accuracy (Table 1).

## SENSING CIRCULATING BIOMARKERS OF NEURODEGENERATION AND NEUROINFLAMMATION

Over the past years, great efforts have been made to identify biomarkers associated with CNS diseases in clinically relevant samples. A biomarker is defined as a measurable biologically plausible parameter, usually being an indicator of an underlying disease mechanism (Atkinson et al., 2001). In addition, an ideal biomarker should also be readily accessible, highly sensitive, and specific and its levels should correlate with disease progression and/or treatment response, allowing disease risk stratification (Bennett and Devarajan, 2016). Biomarker cut-off values determine the clinical sensitivity (ratio of true positives over all individuals with disease) and specificity (ratio of true negatives over all individuals without disease). The Receiver Operating Characteristic (ROC) curve is a graphic display of sensitivity versus (1-specificity), and its Area Under the Curve (AUC) provides a useful measure for optimal cut-off value selection (Parikh and Thiessen-Philbrook, 2014). AUC values for single biomarkers are shown in Table 1. Recent studies suggest that the combination of multiple biomarkers increases the AUC value, therefore increasing the accuracy of the disease diagnostic tests (Spellman et al., 2015; Lue et al., 2016).

Although many neurological studies have relied on the biochemical analysis of CSF, the physiological sample of reference for CNS disorders, these biomarkers are also present in more accessible biological fluids, making sample acquisition less invasive, as exemplified for TNF $\alpha$  and OCBs that are present in higher amounts in tears of PD and MS patients, respectively (Devos et al., 2001; Çomoglu et al., 2013). Nevertheless, this biochemical profiling has mostly relied on microarray technologies (Choi et al., 2008; Craig-Schapiro et al., 2011; Martins et al., 2011; Kozirowski et al., 2012; Edwards et al., 2013; Laske et al., 2013; Burman et al., 2014; Delaby et al., 2015; Cala et al., 2016; Hegen et al., 2016; Lue et al., 2016) and liquid chromatography-mass spectroscopy (Musunuri et al., 2014; Hölttä et al., 2015; Spellman et al., 2015; Paterson et al., 2016) which, although effective for large biomarker panel assessment, are not suitable for point-of-care testing. On the other hand, identification and validation of potential biomarkers is often hindered by their low concentrations in the test fluid and inherent variability across control and patient samples. As such, there is a need for new technologies with lower limit of detection (LOD) and higher sensitivity.

Biosensors are analytical devices capable of converting specific biorecognition events into a measurable signal. Conventional biosensors are composed of a receptor (e.g., antibody, enzyme, and DNA) which specifically recognizes the biomarker (e.g., antigen, enzyme substrate, and DNA) of interest and a transducer which converts biochemical interactions into a quantifiable



electrical signal proportional to biomarker concentrations. Biosensors are commonly classified in electrochemical, optical, piezoelectric, or magnetic, based on the signal transduction mechanism. These technologies have broad applications in health (Zhang et al., 2017; El Harrad et al., 2018), food (Law et al., 2014; Vasilescu and Marty, 2016), and environmental sciences (Rapini and Marrazza, 2017; Kumar et al., 2018). Over the past years, the critical role of inflammation in disease has led researchers to develop biosensors for the specific detection of inflammatory mediators in clinically relevant body fluids. Although most inflammation-targeted biosensors have not been tested in the context of neuroinflammatory diseases, the clinical potential of these technologies is undeniable (Table 2). Recently, Baraket et al. developed an electrochemical biosensor to monitor IL-1 $\beta$  and IL-10 cytokine levels after the implantation of left ventricular assist devices (LVADs) in patients with heart failure while waiting for compatible donors (Baraket et al., 2017). Given the non-biocompatible nature of the LVAD, many patients suffer from acute inflammation in which several pro and anti-inflammatory cytokines are secreted, such as IL-1 $\beta$  and IL-10, respectively. The proposed biosensor was capable of detecting both cytokines within the range of 1–15 pg/mL, relevant to predict the first signs of inflammation (Stumpf et al., 2003).

Increased levels of pro-inflammatory cytokines in the CSF and serum of MS patients can alter the permeability of the blood-brain-barrier and promote T-lymphocyte migration into the brain and disease progression (Khaibullin et al., 2017). Therefore, cytokine detection in minimally invasive body fluids represents an attractive alternative for timely diagnosis of MS patients. Moreover, it allows early identification of relapsing patients and prediction of anti-inflammatory therapy failure, of outmost interest for effective clinical intervention. Elevated serum levels of matrix metalloproteinase-9 (MMP-9) have been associated with ongoing neuroinflammation processes and are indicative of MS relapse (Fainardi et al., 2006). Biela et al. developed an electrochemical biosensor for the sensitive and rapid detection of MMP-9 in clinically relevant ranges (50–400 ng/mL) (Biela et al., 2015). The biosensor was coated with a hydrogel and cross-linked peptides with specific MMP-9 cleavage sites. Exposure to MMP-9 resulted in the degradation of the hydrogel-peptide film and, consequently, produced an electrochemical signal. Importantly, the authors confirmed the specificity of the biosensor for MMP-9 detection against MMP-2, also present in the blood. Additionally, an electrochemical biosensor for IL-12 detection was developed by Bhavsar et al. for automated real-time biomarker analysis (Bhavsar et al., 2009). Although the biosensor was not validated with patient samples, the authors confirmed IL-12 detection in spiked samples of fetal bovine serum, showing a LOD of 3.5 pg/mL, lower than reported values for IL-12 expression in MS patients (Drulović et al., 1998).

In 2015, Chen and co-workers introduced for the first time a biosensor for simultaneous detection of multiple cytokines (Chen et al., 2015) and real-time monitoring of the inflammatory response of two neonates after a cardiopulmonary bypass surgery. This technology is based on a microfluidic surface plasmon resonance (LSPR) sensor capable of detecting multiple analytes through refractometric measurements. The authors

demonstrated parallel multiplex analysis of six cytokines (IL-2, IL-4, IL-6, IL-10, TNF $\alpha$ , interferon  $\gamma$  (IFN $\gamma$ )) with a linear range of detection between 5 and 20 pg/mL, only requiring 1  $\mu$ L of serum sample. Conventionally, nanoplasmonic biosensors are not suitable for point-of-care medical applications due to their limited sensitivity and optical microscope requirements. Nevertheless, the authors employed dark-field imaging with nanorods conjugated with antibodies to improve the sensitivity 10 times more than conventional LSPR chips.

The quantification of inflammatory mediators in minimally invasive samples of patients with neurodegenerative diseases provides valuable clinical information regarding their immune status. Nevertheless, it is insufficient to provide an accurate diagnosis. A comprehensive analysis and quantification of disease-specific biomarkers allied with immune system surveillance may improve patient prognosis by allowing timely and accurate diagnosis while enabling patient stratification for personalized treatment (Table 2).

AD has been by far the most intensely studied neurodegenerative pathology toward the development of effective and sensitive diagnostic platforms with sensors targeting A $\beta$  peptides and oligomers in blood and CSF (Oh et al., 2013; Kim et al., 2016a; Li et al., 2016; Carneiro et al., 2017). Of these, Carneiro et al. recently reported an electrochemical biosensor for the detection of A $\beta$ <sub>1–42</sub> with a LOD of 5.2 pg/mL and wide dynamic range (10–1,000 pg/mL) provided by the use of gold nanoparticles (NPs) (Carneiro et al., 2017). This is particularly significant for the assessment of A $\beta$ <sub>1–42</sub> levels which are below 500 pg/mL in CSF of AD patients (Gagni et al., 2013). Also, Rushworth et al. developed a novel, label-free impedimetric biosensor for the specific detection of A $\beta$ O. A fragment of the cellular prion protein (PrP<sup>C</sup> residues 95–110), which mediates the neuronal binding and toxicity of A $\beta$ O, was used as a recognition element for the specific detection of the oligomers. The biosensor presented a LOD of 0.5 pM and successfully detected cell-derived A $\beta$ O from conditioned media of 7PA2 Chinese Hamster Ovary (CHO) cells that naturally secrete A $\beta$ O (Rushworth et al., 2014). Interestingly, to validate the detection of A $\beta$ O in conditioned media, the authors cultured the cells in the presence of  $\beta$ IV (BACE1 inhibitor), which prevents the generation of A $\beta$ O by inactivation of BACE1. This experiment clearly demonstrated the biosensor's capability of functioning as a reliable source of A $\beta$ O detection for AD diagnosis while also validating its use as a drug screening platform for BACE1. In 2011, Christopheit and colleagues developed a sophisticated drug screening platform with immobilized BACE1 on a plasma membrane-mimicking lipid layer (Christopheit et al., 2011). Vilela et al. reported an optical biosensor based on graphene oxide and upconversion NPs for the specific detection of BACE1 mRNA with a LOD of 500 fM (Vilela et al., 2017). The biosensor showed high specificity for BACE1 detection in spiked samples of healthy patient's plasma and cell lysates as well as long-term storage stability, demonstrating the clinical potential of the sensor.

Although A $\beta$ <sub>1–42</sub> and tau protein are well-established as AD diagnostic markers, they fail to provide the necessary specificity for effective diagnosis and disease progression assessment. Recent evidence suggests that the combination of multiple biomarkers

**TABLE 2 |** Biosensing technologies for neurodegenerative disease diagnostics and monitoring.

Disease	Biomarker	Application	Transduction platform	Sample	LOD	Detection time	References
Inflammation	IL-1 $\beta$	Patient monitoring	Optical	Patient Serum	158.5 fg/mL (PBS) 1 pg/mL (diluted serum)	<15 min (total)	Song et al., 2017
	IL-1 $\beta$ and IL-10	Patient monitoring	Electrochemical	Spiked in buffer	0.3 pg/mL (IL-10) 0.7 pg/mL (IL-1 $\beta$ )	45 min (total)	Baraket et al., 2017
	IL-10	Patient monitoring	Electrochemical	Spiked in buffer	-	30 min (incubation)	Baraket et al., 2016
	IL-6	Drug screening	Electrochemical	Nasopharyngeal carcinoma cell line	-	48 h (total)	Lei et al., 2016
	IL-6	Patient monitoring	Electrical	Spiked in buffer	1.53 pg/mL	Real-time	Huang et al., 2015
	TNF $\alpha$	Patient monitoring	Electrochemical	Spiked Serum	60 pg/mL	20 min (incubation)	Arya and Estrela, 2017
	TNF $\alpha$	Patient monitoring	Electrochemical	Spiked Serum and Saliva	3.7 fg/mL	45 min (incubation)	Aydin et al., 2017
	IL-12	Diagnosis	Electrochemical	Spiked in FBS	3.5 pg/mL	20 min (incubation)	Bhavsar et al., 2009
	MMP-9	Patient monitoring	Electrochemical	Spiked in buffer	15 ng/mL	-	Biela et al., 2015
	IFN $\gamma$	Patient monitoring	Electrochemical	Spiked Serum	0.048 pg/mL	35 min (incubation)	Zhang et al., 2016
	IL-2, IL-4, IL-6, IL-10, TNF $\alpha$ , IFN $\gamma$	Patient monitoring	Optical	Patient Serum	20.56 pg/mL (IL-2) 4.60 pg/mL (IL-4) 11.29 pg/mL (IL-6) 10.97 pg/mL (IL-10) 11.43 pg/mL (TNF $\alpha$ ) 6.46 pg/mL (IFN $\gamma$ )	40 min (total)	Chen et al., 2015
AD	A $\beta$ <sub>1-42</sub> peptide	Diagnosis Patient monitoring	Electrochemical	Spiked in buffer	5.2 pg/mL	10 min (incubation)	Carneiro et al., 2017
	A $\beta$ <sub>1-42</sub> and total A $\beta$ peptides	Diagnosis	Immunomagnetic	Spiked in artificial CSF	5.0 pg/mL	30 min (incubation)	Li et al., 2016
	A $\beta$ <sub>1-42</sub> and A $\beta$ <sub>1-40</sub> peptides	Diagnosis Fundamental studies	Electrical	Spiked in buffer and plasma of mice	0.1 pg/mL	20 min (incubation)	Kim et al., 2016a
	A $\beta$ <sub>1-42</sub> and total A $\beta$ peptides	Diagnosis	Electrochemical	Spiked in serum	1.0 pg/mL	Real-time	Oh et al., 2013
	A $\beta$ <sub>1-42</sub> and A $\beta$ <sub>1-40</sub> peptides and tau protein	Diagnosis	Electrochemical (Multiplex)	Spiked in artificial CSF	5 pM	80 min (total)	Liu et al., 2014
	A $\beta$ oligomer	Diagnosis Patient monitoring	Electrochemical	Spiked in CSF of mice	20 nM	~10 min (incubation)	Prabhukar et al., 2012
	A $\beta$ <sub>1-42</sub> , A $\beta$ <sub>1-40</sub> peptides and tau protein	Diagnosis	Optical (Multiplex with microfluidics)	Patient CSF	3.3 pM (A $\beta$ <sub>1-40</sub> ) 3.5 pM (A $\beta$ <sub>1-42</sub> )	-	Xia et al., 2010
	A $\beta$ oligomer	Diagnosis Patient monitoring	Electrochemical	Conditioned media of 7PA2 CHO cells	34.9 fM (A $\beta$ <sub>1-40</sub> ) 26 fM (A $\beta$ <sub>1-42</sub> ) 23.6 fM (tau protein)	60 min (incubation)	Kim et al., 2018
	A $\beta$ oligomer	Diagnosis Patient monitoring	Optical	Spiked in artificial plasma	0.5 pM	20 min (incubation)	Rushworth et al., 2014
	A $\beta$ oligomer	Diagnosis Patient monitoring	Electrochemical	Spiked in artificial CSF	100 pM	60 min (incubation)	Zhou et al., 2016
	A $\beta$ oligomer	Diagnosis Patient monitoring	Electrochemical	Spiked in Serum and CSF	6 pM	20 min (incubation)	Xing et al., 2017
	A $\beta$ oligomer	Diagnosis Patient monitoring	Optical	Spiked in buffer	0.2 nM	5 min (incubation)	Xia et al., 2016

(Continued)

TABLE 2 | Continued

Disease	Biomarker	Application	Transduction platform	Sample	LOD	Detection time	References
	O-GlcNAc transferase activity	Drug screening Fundamental studies	Electrochemical	Spiked in buffer	–	~120 min (total)	Yang et al., 2017
	Tau protein	Diagnosis	Electrochemical	Spiked in serum	0.03 pM 1000 pg/mL	25 min (incubation) 3 h (incubation)	Wang et al., 2017 Dai et al., 2017
	Acetylcholine	Diagnosis	Electrochemical	Spiked in serum	4 nM	4 s (total)	Chauhan et al., 2017
	Apolipoprotein E	Diagnosis	Electrochemical	Spiked in serum	10 μM	3 min (total)	Moreira et al., 2017
	Fibrinogen	Diagnosis	Optical	Spiked in buffers	5 nM	3 s (total)	Chauhan and Pundir, 2014
	BACE1	Diagnosis Patient Monitoring	Optical	Spiked plasma and cell lysates	286 nM 5 μg/mL 20 ng/mL 500 fM	2h (incubation) 15 min (total) 2h (incubation) 60 min (incubation)	Cheng et al., 2014 Sciaccia et al., 2013 Kim et al., 2016b Vilela et al., 2017
		Drug screening	Optical	BACE1 inhibitors	–	–	Christopeit et al., 2011
PD	Dopamine	Diagnosis	Optical	Spiked in buffer	40 nM	30 min (incubation)	Yildirim and Bayindir, 2014
			Electrical	Spiked samples	10 pM (PBS) 1 nM (Serum)	Real time (total)	Park et al., 2014
			Electrical	Spiked in buffer	100 fM	Real time (total)	Lee et al., 2015
			Optical	Spiked in CSF	0.830 nM	5 min (incubation)	Govindaraju et al., 2017
	Dopamine and Uric acid	Diagnosis	Electrochemical	Patient Serum	1 nM	–	Yue et al., 2014
	α-synuclein	Diagnosis	Photoelectrochemical	Spiked in buffer	34 pg/mL	60 min (incubation)	An et al., 2010
	Thrombin	Diagnosis	Electrochemical	Patient blood and CSF	1 fM	3h (total)	Heydari-Bafrooi et al., 2016
	Acetylcholinesterase	Drug screening	Photoelectrochemical	(R)-Sal, (R)-NMSal	–	–	Huang et al., 2013
MS	Autoantibodies	Diagnosis Patient monitoring	Optical	Patient serum	–	4 min (incubation)	Real-Fernández et al., 2012
	Myelin Basic Protein	Diagnosis	Electrochemical	Patient serum and CSF	0.1495 ng/mL (gelatin-TiO <sub>2</sub> -MBP)	30 min (incubation) (gelatin-TiO <sub>2</sub> -MBP)	Derkus et al., 2013
	Tau protein	Diagnosis	Electrochemical	Spiked serum and CSF	0.30 nM (Myelin basic protein) 0.15 nM (Tau protein)	–	Derkus et al., 2017

LOD, Limit of detection; Alp, Amyloid; (R)-Sal: 1(R)-methyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline; (R)-NMSal: 1(R),2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetra-hydroisoquinoline.

may provide a more reliable and accurate diagnosis. For instance, Lewczuk et al. verified that  $A\beta_{1-42}/A\beta_{1-40}$  concentration ratio is a better predictor of AD than  $A\beta_{1-42}$  alone (Lewczuk et al., 2015). Given the preponderant role of neuroinflammation in AD, monitoring circulating inflammatory mediators, such as cytokines, chemokines, and growth factors could provide valuable insights for early screening and treatment response evaluation (Laske et al., 2013; Delaby et al., 2015). Nevertheless, multiplex biosensor development for AD is still scarce, with only a few studies focused on  $A\beta$  detection (Xia et al., 2010; Liu et al., 2014).

Currently available biosensors are targeting markers such as the acetylcholine neurotransmitter (Chauhan and Pundir, 2014; Chauhan et al., 2017; Moreira et al., 2017), which is essential for memory processing, fibrinogen (Kim et al., 2016b), a clotting protein associated with  $A\beta$  aggregation (Cortes-Canteli et al., 2012) and APOE (Sciaccia et al., 2013; Cheng et al., 2014). Nevertheless, single biomarker detection has fallen short for reliable AD diagnosis. Recently, Yang et al. devised an electrochemical biosensor for small-molecule O-GlcNAc transferase (OGT) inhibitor screening as an alternative to the conventional approaches (Yang et al., 2017). As it is known that aberrant activity of OGT may be involved in neurodegeneration and AD (Yuzwa and Vocadlo, 2014), the screening of OGT inhibitors could potentially lead to the development of targeted therapeutics and protein glycosylation pathway research. In this work, the authors studied the impact of concentration and incubation time of benzoxazolinone (BZX) and alloxan, which are known OGT inhibitors. This proof-of-concept study paves the way for the optimization of a label-free integrated platform for high-throughput drug screening of OGT inhibitors, specifically if multiple analytes or enzymes for O-linked glycosylation are analyzed simultaneously.

For PD, Yildirim et al. reported an optical technique for the detection of dopamine (DA) based on its oxidation and subsequent aggregation into NPs (polydopamine) (Yildirim and Bayindir, 2014). Interestingly, these NPs hold fluorescent properties, which allow the determination of DA concentrations with a detection limit of 40 nM. Additionally, Yue et al. reported the development of an electrochemical biosensor of vertically aligned ZnO nanowires on a 3D graphene foam for the detection of DA, uric acid (UA), and ascorbic acid (AA) (Yue et al., 2014). The use of 3D graphene foam enhanced electron transport due to its high conductivity and the vertical ZnO nanowires provided higher surface area. Importantly, the authors demonstrated the selectivity of the assay for DA, UA, and AA detection. The development of electrochemical biosensors for the specific detection of these molecules is particularly challenging, as they co-exist in serum with similar redox potential, thus limiting their oxidative peak discrimination. Of note, they verified that the UA serum levels for healthy individuals ranged from 325 to 385  $\mu\text{M}$ , while PD patients presented values between 245 and 285  $\mu\text{M}$ , suggesting that UA could be a potential marker for PD. Sensitive detection of DA has also been performed using electrolyte-gated field-effect transistors (EGFETs) with nanovesicles in a conducting polymer with immobilized human DA receptor D1 (Park et al., 2014). The authors reported a minimum detectable

level of 1 nM for spiked DA in human serum, suggesting that this biosensor is suitable for PD diagnosis as DA reported values for PD are within the nM range. In a similar approach, Lee et al. developed a sensitive and reusable EGFET for DA detection using conductive polymer NPs coated with Pt particles (Lee et al., 2015), which act as catalysts for DA oxidation, enhancing signal detection, response time, and sensitivity. This sensor was able to detect DA in the fM concentration with minimal interference of AA or UA.

Although  $\alpha$ -syn has been the most intensely studied and recognized biomarker for PD, its application in biosensing is very limited. A photoelectrochemical biosensor was developed by An et al. based on Au-doped  $\text{TiO}_2$  nanotube arrays for sensitive  $\alpha$ -syn quantification with a detection limit of 34 pg/mL (An et al., 2010). Thrombin was reported to induce apoptosis of dopaminergic neurons in rat *substantia nigra* (Choi et al., 2003) and microglia activation by inducing the expression of pro-inflammatory mediators TNF $\alpha$ , IL-1 $\beta$ , IL-6, and nitric oxide (Lee et al., 2005). Therefore, the detection and quantification of thrombin in the blood or CSF samples of PD patients could predict ongoing neuroinflammation while enabling disease diagnosis. An electrochemical biosensor for thrombin detection was developed by Bafrooei et al. using aptamers functionalized on a nanocomposite of multiwalled carbon nanotubes and  $\text{TiO}_2$  NPs (Heydari-Bafrooei et al., 2016). The aptasensor showed high specificity, sensitivity (in fM range) in blood, or CSF of PD patients.

The heterogeneous nature of MS, characterized by distinct patterns associated with the demyelination process, makes it highly improbable that a single diagnostic marker is capable of covering the full spectrum of MS subtypes (Lucchinetti et al., 2000). Lolli et al. developed a synthetic glycoprotein antigen probe, CSF114(Glc), for the specific recognition of autoantibodies present in the serum of MS patients (Lolli et al., 2005). The authors proved that the antibodies specific for CSF114(Glc) recognized myelin and oligodendrocyte autoantigens in human brain tissue. This knowledge enabled the development of a specific method for the identification of MS patients with antibody-mediated demyelination, a specific subset of MS patients. The same group later reported the development of a gold surface plasmon resonance (SPR) biosensor with covalently immobilized CSF114(Glc) for real-time MS diagnosis from serum (Real-Fernández et al., 2012). This SPR biosensor presented a mild sensitivity (36%) and elevated specificity (95%) relative to the identification of MS patients vs. healthy blood donors. Other than MS diagnosis, multiple autoantibody identification, and further clinical correlation could potentially be used to direct therapy and monitor its response.

## CONCLUSION

An increasing number of studies are uncovering the beneficial and detrimental roles of microglia in neurodegenerative disease onset and progression. Pro-inflammatory cytokines can be used



in combination with classical biomarkers for neurodegenerative and neuroinflammatory disease diagnostics and monitoring of disease progression. Technologies for simultaneous detection and quantification of different biomarkers are rapidly developing and future devices are aimed at bringing valuable advantages, specifically related to lower sample volumes, detection time and limits, higher specificity and sensitivity. Decreasing the need for biological samples processing, while integrating biosensing platforms in portable lab-on-a-chip systems would, in turn, allow point-of-care use by semi-skilled operators toward real-time and *in situ* early diagnostics of neuroinflammatory and neurodegenerative diseases. Altogether, these advantages will surely bring great benefits for both academic and medical fields.

## AUTHOR CONTRIBUTIONS

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.

## REFERENCES

- An, Y., Tang, L., Jiang, X., Chen, H., Yang, M., Jin, L., et al. (2010). A photoelectrochemical immunosensor based on au-doped TiO<sub>2</sub> nanotube arrays for the detection of alpha-synuclein. *Chemistry* 16, 14439–14446. doi: 10.1002/chem.201001654
- Andersen, A. D., Binzer, M., Stenager, E., and Gramsbergen, J. B. (2017). Cerebrospinal fluid biomarkers for Parkinson's disease - a systematic review. *Acta Neurol. Scand.* 135, 34–56. doi: 10.1111/ane.12590
- Arellano, G., Acuña, E., Reyes, L. I., Ottum, P. A., Sarno, P., and De, Villarreal, L., et al. (2017). Th1 and Th17 cells and associated cytokines discriminate among clinically isolated syndrome and multiple sclerosis phenotypes. *Front. Immunol.* 8:753. doi: 10.3389/fimmu.2017.00753
- Arya, S. K., and Estrela, P. (2017). Electrochemical immunosensor for tumor necrosis factor-alpha detection in undiluted serum. *Methods* 116, 125–131. doi: 10.1016/j.ymeth.2016.12.001
- Atkinson, A. J., Colburn, W. A., DeGruttola, V. G., DeMets, D. L., Downing, G. J., Hoth, D. F., et al. (2001). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. *Clin. Pharmacol. Ther.* 69, 89–95. doi: 10.1067/mcp.2001.113989
- Aydin, E. B., Aydin, M., and Sezginçürk, M. K. (2017). A highly sensitive immunosensor based on ITO thin films covered by a new semi-conductive conjugated polymer for the determination of TNF $\alpha$  in human saliva and serum samples. *Biosens. Bioelectron.* 97, 169–176. doi: 10.1016/j.bios.2017.05.056
- Baraket, A., Lee, M., Zine, N., Sigaud, M., Bausells, J., and Errachid, A. (2017). A fully integrated electrochemical biosensor platform fabrication process for cytokines detection. *Biosens. Bioelectron.* 93, 170–175. doi: 10.1016/j.bios.2016.09.023
- Baraket, A., Lee, M., Zine, N., Yaakoubi, N., Bausells, J., and Errachid, A. (2016). A flexible electrochemical micro lab-on-chip: application to the detection of interleukin-10. *Microchim. Acta* 183, 2155–2162. doi: 10.1007/s00604-016-1847-y
- Bennett, M. R., and Devarajan, P. (2016). "Characteristics of an ideal biomarker of kidney diseases," in *Biomarkers of Kidney Disease*, ed C. L. Edelstein (San Diego, CA: Elsevier), 1–20. doi: 10.1016/B978-0-12-803014-1.00001-7
- Bhavsar, K., Fairchild, A., Alonas, E., Bishop, D. K., La Belle, J. T., Sweeney, J., et al. (2009). A cytokine immunosensor for Multiple Sclerosis detection based upon label-free electrochemical impedance spectroscopy using electroplated printed circuit board electrodes. *Biosens. Bioelectron.* 25, 506–509. doi: 10.1016/j.bios.2009.07.017
- Biela, A., Watkinson, M., Meier, U. C., Baker, D., Giovannoni, G., Becer, C. R., et al. (2015). Disposable MMP-9 sensor based on the degradation of peptide cross-linked hydrogel films using electrochemical impedance spectroscopy. *Biosens. Bioelectron.* 68, 660–667. doi: 10.1016/j.bios.2015.01.060

## FUNDING

IM and AC acknowledge the financial support from the Marie Curie COFUND Programme NanoTRAINforGrowth from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement no 600375. This article is a result of the project Nanotechnology based functional solutions (NORTE-01-0145-FEDER-000019), co-financed by Norte Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, through the European Regional Development Fund (ERDF). PM acknowledges the Ph.D. fellowship from Fundação para a Ciência e Tecnologia, Portugal (PD/BD/105751/2014).

## ACKNOWLEDGMENTS

The authors acknowledge Helena Sofia Domingues for critical reading of the manuscript.

- Bradshaw, E. M., Chibnik, L. B., Keenan, B. T., Ottoboni, L., Raj, T., Tang, A., et al. (2013). CD33 Alzheimer's disease locus: Altered monocyte function and amyloid biology. *Nat. Neurosci.* 16, 848–850. doi: 10.1038/nn.3435
- Brochard, V., Combadière, B., Prigent, A., Laouar, Y., Perrin, A., Beray-Berthet, V., et al. (2009). Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. *J. Clin. Invest.* 119, 182–192. doi: 10.1172/JCI36470
- Brockmann, K., Schulte, C., Schneiderhan-Marra, N., Apel, A., Pont-Sunyer, C., Vilas, D., et al. (2017). Inflammatory profile discriminates clinical subtypes in LRRK2-associated Parkinson's disease. *Eur. J. Neurol.* 24, 427–e6. doi: 10.1111/ene.13223
- Bronzuoli, M. R., Iacomino, A., Steardo, L., and Scuderi, C. (2016). Targeting neuroinflammation in Alzheimer's disease. *J. Inflamm. Res.* 9, 199–208. doi: 10.2147/JIR.S86958
- Brosseron, F., Krauthausen, M., Kummer, M., and Heneka, M. T. (2014). Body fluid cytokine levels in mild cognitive impairment and Alzheimer's disease: a comparative overview. *Mol. Neurobiol.* 50, 534–544. doi: 10.1007/s12035-014-8657-1
- Burman, J., Svensson, E., Fransson, M., Loskog, A. S. I., Zetterberg, H., Raininko, R., et al. (2014). The cerebrospinal fluid cytokine signature of multiple sclerosis: A homogenous response that does not conform to the Th1/Th2/Th17 convention. *J. Neuroimmunol.* 277, 153–159. doi: 10.1016/j.jneuroim.2014.10.005
- Cala, C. M., Moseley, C. E., Steele, C., Dowdy, S. M., Cutter, G. R., Ness, J. M., et al. (2016). T cell cytokine signatures: biomarkers in pediatric multiple sclerosis. *J. Neuroimmunol.* 297, 1–8. doi: 10.1016/j.jneuroim.2016.04.015
- Carneiro, P., Loureiro, J., Delerue-Matos, C., Morais, S., and do Carmo Pereira, M. (2017). Alzheimer's disease: Development of a sensitive label-free electrochemical immunosensor for detection of amyloid beta peptide. *Sensors Actu. B Chem.* 239, 157–165. doi: 10.1016/j.snb.2016.07.181
- Chauhan, N., Chawla, S., Pundir, C. S., and Jain, U. (2017). An electrochemical sensor for detection of neurotransmitter-acetylcholine using metal nanoparticles, 2D material and conducting polymer modified electrode. *Biosens. Bioelectron.* 89, 377–383. doi: 10.1016/j.bios.2016.06.047
- Chauhan, N., and Pundir, C. S. (2014). Amperometric determination of acetylcholine—A neurotransmitter, by chitosan/gold-coated ferric oxide nanoparticles modified gold electrode. *Biosens. Bioelectron.* 61, 1–8. doi: 10.1016/j.bios.2014.04.048
- Chen, P., Chung, M. T., McHugh, W., Nidetz, R., Li, Y., Fu, J., et al. (2015). Multiplex serum cytokine immunoassay using nanoplasmonic biosensor microarrays. *ACS Nano* 9, 4173–4181. doi: 10.1021/acsnano.5b00396
- Cheng, X. R., Hau, B. Y., Endo, T., and Kerman, K. (2014). Au nanoparticle-modified DNA sensor based on simultaneous electrochemical impedance

- spectroscopy and localized surface plasmon resonance. *Biosens. Bioelectron.* 53, 513–518. doi: 10.1016/j.bios.2013.10.003
- Choi, C., Jeong, J. H., Jang, J. S., Choi, K., Kwon, J. L., Kwon, J., et al. (2008). Multiplex analysis of cytokines in the serum and cerebrospinal fluid of patients with Alzheimer's disease by color-coded bead technology. *J. Clin. Neurol.* 4, 84–88. doi: 10.3988/jcn.2008.4.2.84
- Choi, I.-Y., Lee, P., Adany, P., Hughes, A. J., Belliston, S., Denney, D. R., et al. (2017). *In vivo* evidence of oxidative stress in brains of patients with progressive multiple sclerosis. *Ther. Adv. Hematol.* 8, 153–156. doi: 10.1177/1352458517711568
- Choi, S.-H., Le, D. Y., Ryu, J. K., Kim, J., Joe, E. H., and Jin, B. K. (2003). Thrombin induces nigral dopaminergic neurodegeneration *in vivo* by altering expression of death-related proteins. *Neurobiol. Dis.* 14, 181–193. doi: 10.1016/S0969-9961(03)00085-8
- Christopeit, T., Stenberg, G., Gossas, T., Nyström, S., Baraznenok, V., Lindström, E., et al. (2011). A surface plasmon resonance-based biosensor with full-length BACE1 in a reconstituted membrane. *Anal. Biochem.* 414, 14–22. doi: 10.1016/j.ab.2011.02.041
- Çomoglu, S. S., Güven, H., Acar, M., Öztürk, G., and Koçer, B. (2013). Tear levels of tumor necrosis factor- $\alpha$  in patients with Parkinson's disease. *Neurosci. Lett.* 553, 63–67. doi: 10.1016/j.neulet.2013.08.019
- Cortes-Canteli, M., Zamolodchikov, D., Ahn, H. J., Strickland, S., and Norris, E. H. (2012). Fibrinogen and altered hemostasis in Alzheimer's disease. *J. Alzheimer's Dis.* 32, 599–608. doi: 10.3233/JAD-2012-120820
- Craig-Schapiro, R., Kuhn, M., Xiong, C., Pickering, E. H., Liu, J., Misko, T. P., et al. (2011). Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. *PLoS ONE* 6:e18850. doi: 10.1371/journal.pone.0018850
- Crehan, H., Hardy, J., and Pocock, J. (2013). Blockage of CR1 prevents activation of rodent microglia. *Neurobiol. Dis.* 54, 139–149. doi: 10.1016/j.nbd.2013.02.003
- Crotti, A., and Ransohoff, R. M. (2016). Microglial physiology and pathophysiology: insights from genome-wide transcriptional profiling. *Immunity* 44, 505–515. doi: 10.1016/j.immuni.2016.02.013
- D'Ambrosio, A., Pontecorvo, S., Colasanti, T., Zamboni, S., Francia, A., and Margutti, P. (2015). Peripheral blood biomarkers in multiple sclerosis. *Autoimmun. Rev.* 14, 1097–1110. doi: 10.1016/j.autrev.2015.07.014
- Dai, Y., Molazemhosseini, A., and Liu, C. C. (2017). A single-use, *in vitro* biosensor for the detection of t-tau protein, a biomarker of neuro-degenerative disorders, in pbs and human serum using differential pulse voltammetry (DPV). *Biosensors* 7, 1–11. doi: 10.3390/bios7010010
- Dansokho, C., and Heneka, M. T. (2017). Neuroinflammatory responses in Alzheimer's disease. *J. Neural Transm.* 125, 771–779. doi: 10.1007/s00702-017-1831-7
- Delaby, C., Gabelle, A., Blum, D., Schraen-Maschke, S., Moulinier, A., Boulanghien, J., et al. (2015). Central nervous system and peripheral inflammatory processes in Alzheimer's disease: biomarker profiling approach. *Front. Neurol.* 6:181. doi: 10.3389/fneur.2015.00181
- Delgado-Alvarado, M., Gago, B., Gorostidi, A., Jiménez-Urbietta, H., Dacosta-Aguayo, R., Navalpotro-Gómez, I., et al. (2017). Tau/ $\alpha$ -synuclein ratio and inflammatory proteins in Parkinson's disease: an exploratory study. *Mov. Disord.* 32, 1066–1073. doi: 10.1002/mds.27001
- Dendrou, C. A., Fugger, L., and Friese, M. A. (2015). Immunopathology of multiple sclerosis. *Nat. Rev. Immunol.* 15, 545–558. doi: 10.1038/nri3871
- Derkus, B., Acar Bozkurt, P., Tulu, M., Emregul, K. C., Yucesan, C., and Emregul, E. (2017). Simultaneous quantification of myelin basic protein and tau proteins in cerebrospinal fluid and serum of multiple Sclerosis patients using nanoimmunosensor. *Biosens. Bioelectron.* 89, 781–788. doi: 10.1016/j.bios.2016.10.019
- Derkus, B., Emregul, E., Yucesan, C., and Cebesoy Emregul, K. (2013). Myelin basic protein immunosensor for multiple sclerosis detection based upon label-free electrochemical impedance spectroscopy. *Biosens. Bioelectron.* 46, 53–60. doi: 10.1016/j.bios.2013.01.060
- Devos, D., Forzy, G., de Seze, J., Cailleux, S., Louchart, P., Gallois, P., et al. (2001). Silver stained isoelectrophoresis of tears and cerebrospinal fluid in multiple sclerosis. *J. Neurol.* 248, 672–675. doi: 10.1007/PL00007833
- Drulović, J., Mostarica-Stojković, M., Lević, Z., Mesaros, S., Stojavljević, N., Popadić, D., et al. (1998). Serum interleukin-12 levels in patients with multiple sclerosis. *Neurosci. Lett.* 251, 129–132. doi: 10.1016/S0304-3940(98)00520-5
- Dufek, M., Hamanová, M., Lokaj, J., Goldemund, D., Rektorová, I., Michálková, Z., et al. (2009). Serum inflammatory biomarkers in Parkinson's disease. *Park. Relat. Disord.* 15, 318–320. doi: 10.1016/j.parkreldis.2008.05.014
- Dursun, E., Gezen-Ak, D., Hanagasi, H., Bilgiç, B., Lohmann, E., Ertan, S., et al. (2015). The interleukin 1 alpha, interleukin 1 beta, interleukin 6 and alpha-2-macroglobulin serum levels in patients with early or late onset Alzheimer's disease, mild cognitive impairment or Parkinson's disease. *J. Neuroimmunol.* 283, 50–57. doi: 10.1016/j.jneuroim.2015.04.014
- Edwards, K. R., Goya, J., Plavina, T., Czerkowiec, J., Goelz, S., Ranger, A., et al. (2013). Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis. *PLoS ONE* 8:e81007. doi: 10.1371/journal.pone.0081007
- El Harrad, L., Bourais, I., Mohammadi, H., and Amine, A. (2018). Recent advances in electrochemical biosensors based on enzyme inhibition for clinical and pharmaceutical applications. *Sensors* 18:164. doi: 10.3390/s18010164
- Fainardi, E., Castellazzi, M., Bellini, T., Manfrinato, M. C., Baldi, E., Casetta, I., et al. (2006). Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis. *Mult. Scler.* 12, 294–301. doi: 10.1191/135248506ms12740a
- Farfel, J. M., Yu, L., Buchman, A. S., Schneider, J. A., De Jager, P. L., and Bennett, D. A. (2016). Relation of genomic variants for Alzheimer disease dementia to common neuropathologies. *Neurology* 87, 489–496. doi: 10.1212/WNL.0000000000002909
- Fonseca, M. I., Chu, S.-H., Hernandez, M. X., Fang, M. J., Modarresi, L., Selvan, P., et al. (2017). Cell-specific deletion of C1qa identifies microglia as the dominant source of C1q in mouse brain. *J. Neuroinflammation* 14:48. doi: 10.1186/s12974-017-0814-9
- Gagni, P., Sola, L., Cretich, M., and Chiari, M. (2013). Development of a high-sensitivity immunoassay for amyloid-beta 1-42 using a silicon microarray platform. *Biosens. Bioelectron.* 47, 490–495. doi: 10.1016/j.bios.2013.03.077
- Gerhard, A., Pavese, N., Hotton, G., Turkheimer, F., Es, M., Hammers, A., et al. (2006). *In vivo* imaging of microglial activation with [<sup>11</sup>C](R)-PK11195 PET in idiopathic Parkinson's disease. *Neurobiol. Dis.* 21, 404–412. doi: 10.1016/j.nbd.2005.08.002
- Ginhoux, F., and Williams, M. (2016). Tissue-Resident Macrophage ontogeny and homeostasis. *Immunity* 44, 439–449. doi: 10.1016/j.immuni.2016.02.024
- Giovannoni, G. (2014). "Chapter 30: Cerebrospinal fluid analysis," in *Multiple Sclerosis and Related Disorders*, ed D. S. Goodin (San Diego, CA: Elsevier), 681–702. doi: 10.1016/B978-0-444-52001-2.00029-7
- Govindaraju, S., Ankireddy, S. R., Viswanath, B., Kim, J., Yun, K., Thirumalraj, B., et al. (2017). Fluorescent gold nanoclusters for selective detection of dopamine in cerebrospinal fluid. *Sci. Rep.* 7, 1–12. doi: 10.1038/srep40298
- Griciuc, A., Serrano-Pozo, A., Parrado, A. R., Lesinski, A. N., Asselin, C. N., Mullin, K., et al. (2013). Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta. *Neuron* 78, 631–643. doi: 10.1016/j.neuron.2013.04.014
- Griffin, W. S. T., Liu, L., Li, Y., Mrak, R. E., and Barger, S. W. (2006). Interleukin-1 mediates Alzheimer and Lewy body pathologies. *J. Neuroinflammation* 3:5. doi: 10.1186/1742-2094-3-5
- Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogava, E., Majounie, E., et al. (2013). TREM2 variants in Alzheimer's disease. *N. Engl. J. Med.* 368, 117–127. doi: 10.1056/NEJMoal211851
- Guillot-Sestier, M. V., and Town, T. (2017). Let's make microglia great again in neurodegenerative disorders. *J. Neural. Transm.* 125, 751–770. doi: 10.1007/s00702-017-1792-x
- Hansson, O., Janelidze, S., Hall, S., Magdalinou, N., Lees, A. J., Andreasson, U., et al. (2017). Blood-based NFL. *Neurology* 88, 930–937. doi: 10.1212/WNL.0000000000003680
- Hay, S. I., Abajobir, A. A., Abate, K. H., Abbafati, C., Abbas, K. M., Abd-Allah, F., et al. (2017). Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. *Lancet* 390, 1260–1344. doi: 10.1016/S0140-6736(17)32130-X
- Hegen, H., Adrianto, I., Lessard, C. J., Millionig, A., Bertolotto, A., Comabella, M., et al. (2016). Cytokine profiles show heterogeneity of interferon-beta response in multiple sclerosis patients. *Neurol. Neuroimmunol. Neuroinflammation* 3:e202. doi: 10.1212/NXI.0000000000000202

- Heneka, M. T., Kummer, M. P., Stutz, A., Delekate, A., Schwartz, S., Vieira-Saecker, A., et al. (2013). NLRP3 is activated in Alzheimer's disease and contributes to pathology in APP/PS1 mice. *Nature* 493, 674–678. doi: 10.1038/nature11729
- Hesse, R., Wahler, A., Gummert, P., Kirschmer, S., Otto, M., Tumani, H., et al. (2016). Decreased IL-8 levels in CSF and serum of AD patients and negative correlation of MMSE and IL-1 $\beta$ . *BMC Neurol.* 16:185. doi: 10.1186/s12883-016-0707-z
- Heydari-Bafrooi, E., Amini, M., and Ardakani, M. H. (2016). An electrochemical aptasensor based on TiO<sub>2</sub>/MWCNT and a novel synthesized Schiff base nanocomposite for the ultrasensitive detection of thrombin. *Biosens. Bioelectron.* 85, 828–836. doi: 10.1016/j.bios.2016.06.012
- Hölttä, M., Minthon, L., Hansson, O., Holmén-Larsson, J., Pike, I., Ward, M., et al. (2015). An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease. *J. Proteome Res.* 14, 654–663. doi: 10.1021/pr501076j
- Hong, S., Beja-Glasser, V. F., Nfonoyim, B. M., Frouin, A., Li, S., Ramakrishnan, S., et al. (2016). Complement and microglia mediate early synapse loss in Alzheimer mouse models. *Science* 352, 712–716. doi: 10.1126/science.aad8373
- Honig, L. S., Vellas, B., Woodward, M., Boada, M., Bullock, R., Borrie, M., et al. (2018). Trial of solanezumab for mild dementia due to Alzheimer's Disease. *N. Engl. J. Med.* 378, 321–330. doi: 10.1056/NEJMoa1705971
- Housley, W. J., Pitt, D., and Hafler, D. A. (2015). Biomarkers in multiple sclerosis. *Clin. Immunol.* 161, 51–58. doi: 10.1016/j.clim.2015.06.015
- Huang, J., Chen, H., Niu, W., Fam, D. W. H., Palaniappan, A., Larisika, M., et al. (2015). Highly manufacturable graphene oxide biosensor for sensitive Interleukin-6 detection. *RSC Adv.* 5, 39245–39251. doi: 10.1039/C5RA05854F
- Huang, Q., Chen, H., Xu, L., Lu, D., Tang, L., Jin, L., et al. (2013). Visible-light-activated photoelectrochemical biosensor for the study of acetylcholinesterase inhibition induced by endogenous neurotoxins. *Biosens. Bioelectron.* 45, 292–299. doi: 10.1016/j.bios.2013.01.075
- Huynh, R. A., and Mohan, C. (2017). Alzheimer's disease: biomarkers in the genome, blood, and cerebrospinal fluid. *Front. Neurol.* 8:102. doi: 10.3389/fneur.2017.00102
- Inglese, M., and Petracca, M. (2013). Imaging multiple sclerosis and other neurodegenerative diseases. *Prion* 7, 47–54. doi: 10.4161/pri.22650
- Kalia, L. V., and Lang, A. E. (2015). Parkinson's disease. *Lancet* 386, 896–912. doi: 10.1016/S0140-6736(14)61393-
- Khaibullin, T., Ivanova, V., Martynova, E., Cherepnev, G., Khabirov, F., Granatov, E., et al. (2017). Elevated levels of proinflammatory cytokines in cerebrospinal fluid of multiple sclerosis patients. *Front. Immunol.* 8:531. doi: 10.3389/fimmu.2017.00531
- Kim, H., Lee, J. U., Song, S., Kim, S., and Sim, S. J. (2018). A shape-code nanoplasmonic biosensor for multiplex detection of Alzheimer's disease biomarkers. *Biosens. Bioelectron.* 101, 96–102. doi: 10.1016/j.bios.2017.10.018
- Kim, J., Chae, M.-S., Lee, S. M., Jeong, D., Lee, B. C., Lee, J. H., et al. (2016a). Wafer-scale high-resolution patterning of reduced graphene oxide films for detection of low concentration biomarkers in plasma. *Sci. Rep.* 6:31276. doi: 10.1038/srep31276
- Kim, J., Kim, S., Nguyen, T. T., Lee, R., Li, T., Yun, C., et al. (2016b). Label-free quantitative immunoassay of fibrinogen in Alzheimer disease patient plasma using fiber optical surface plasmon resonance. *J. Electron. Mater.* 45, 2354–2360. doi: 10.1007/s11664-015-4292-5
- Kothur, K., Wienholt, L., Brilot, F., and Dale, R. C. (2016). CSF cytokines/chemokines as biomarkers in neuroinflammatory CNS disorders: a systematic review. *Cytokine* 77, 227–237. doi: 10.1016/j.cyto.2015.10.001
- Koziorowski, D., Tomasiuk, R., Szlufik, S., and Friedman, A. (2012). Inflammatory cytokines and NT-proCNP in Parkinson's disease patients. *Cytokine* 60, 762–766. doi: 10.1016/j.cyto.2012.07.030
- Kumar, N., Hu, Y., Singh, S., and Mizaikoff, B. (2018). Emerging biosensor platforms for the assessment of water-borne pathogens. *Analyst* 143, 359–373. doi: 10.1039/C7AN00983F
- Labzin, L. I., Heneka, M. T., and Latz, E. (2018). Innate immunity and neurodegeneration. *Annu. Rev. Med.* 69, 437–449. doi: 10.1146/annurev-med-050715-104343
- Lane, C. A., Hardy, J., and Schott, J. M. (2018). Alzheimer's disease. *Eur. J. Neurol.* 25, 59–70. doi: 10.1111/ene.13439
- Laske, C., Schmohl, M., Leyhe, T., Stransky, E., Maetzler, W., Berg, D., et al. (2013). Immune profiling in blood identifies sTNF-R1 performing comparably well as biomarker panels for classification of Alzheimer's disease patients. *J. Alzheimer's Dis.* 34, 367–375. doi: 10.3233/JAD-121558
- Law, J. W. F., Mutalib, N. S. A., Chan, K. G., and Lee, L. H. (2014). Rapid methods for the detection of foodborne bacterial pathogens: principles, applications, advantages and limitations. *Front. Microbiol.* 5:770. doi: 10.3389/fmicb.2014.00770
- Lee, D. Y., Oh, Y. J., and Jin, B. K. (2005). Thrombin-activated microglia contribute to death of dopaminergic neurons in rat mesencephalic cultures: dual roles of mitogen-activated protein kinase signaling pathways. *Glia* 51, 98–110. doi: 10.1002/glia.20190
- Lee, H., James, W. S., and Cowley, S. A. (2017). LRRK2 in peripheral and central nervous system innate immunity: its link to Parkinson's disease. *Biochem. Soc. Trans.* 45, 131–139. doi: 10.1042/BST20160262
- Lee, J. S., Oh, J., Kim, S. G., and Jang, J. (2015). Highly sensitive and selective field-effect-transistor nonenzyme dopamine sensors based on Pt/conducting polymer hybrid nanoparticles. *Small* 11, 2399–2406. doi: 10.1002/smll.201403263
- Lei, K. F., Tseng, H. P., Lee, C. Y., and Tsang, N. M. (2016). Quantitative study of cell invasion process under extracellular stimulation of cytokine in a microfluidic device. *Sci. Rep.* 6, 6–13. doi: 10.1038/srep25557
- Leszek, J. E., Barreto, G., Gsiorowski, K., Koutsouraki, E., Ávila-Rodrigues, M., and Aliev, G. (2016). Inflammatory mechanisms and oxidative stress as key factors responsible for progression of neurodegeneration: role of brain innate immune system. *CNS Neurol. Disord. Drug Targets* 15, 329–336. doi: 10.2174/1871527315666160202125914
- Lewczuk, P., Leleental, N., Spitzer, P., Maler, J. M., and Kornhuber, J. (2015). Amyloid- $\beta$  42/40 cerebrospinal fluid concentration ratio in the diagnostics of Alzheimer's disease: validation of two novel assays. *J. Alzheimer's Dis.* 43, 183–191. doi: 10.3233/JAD-140771
- Li, S.-S., Lin, C.-W., Wei, K.-C., Huang, C.-Y., Hsu, P.-H., Liu, H.-L., et al. (2016). Non-invasive screening for early Alzheimer's disease diagnosis by a sensitively immunomagnetic biosensor. *Sci. Rep.* 6:25155. doi: 10.1038/srep25155
- Liddel, S. A., Guttenplan, K. A., Clarke, L. E., Bennett, F. C., Bohlen, C. J., Schirmer, L., et al. (2017). Neurotoxic reactive astrocytes are induced by activated microglia. *Nature* 541, 481–487. doi: 10.1038/nature21029
- Liu, L., He, Q., Zhao, F., Xia, N., Liu, H., Li, S., et al. (2014). Competitive electrochemical immunoassay for detection of beta-amyloid (1-42) and total beta-amyloid peptides using p-aminophenol redox cycling. *Biosens. Bioelectron.* 51, 208–212. doi: 10.1016/j.bios.2013.07.047
- Lolli, F., Mulinacci, B., Carotenuto, A., Bonetti, B., Sabatino, G., Mazzanti, B., et al. (2005). An N-glycosylated peptide detecting disease-specific autoantibodies, biomarkers of multiple sclerosis. *Proc. Natl. Acad. Sci. U.S.A.* 102, 10273–10278. doi: 10.1073/pnas.0503178102
- Lucchinetti, C., Brück, W., Parisi, J., Scheithauer, B., Rodriguez, M., and Lassmann, H. (2000). Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. *Ann. Neurol.* 47, 707–717. doi: 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q
- Lue, L.-F., Schmitz, C. T., Snyder, N. L., Chen, K., Walker, D. G., Davis, K. J., et al. (2016). Converging mediators from immune and trophic pathways to identify Parkinson disease dementia. *Neurol. Neuroimmunol. Neuroinflammation* 3:e193. doi: 10.1212/NXI.0000000000000193
- Luo, C., Jian, C., Liao, Y., Huang, Q., Wu, Y., Liu, X., et al. (2017). The role of microglia in multiple sclerosis. *Neuropsychiatr. Dis. Treat.* 13, 1661–1667. doi: 10.2147/NDT.S140634
- Martins, T. B., Rose, J. W., Jaskowski, T. D., Wilson, A. R., Husebye, D., Seraj, H. S., et al. (2011). Analysis of proinflammatory and anti-inflammatory cytokine serum concentrations in patients with multiple sclerosis by using a multiplexed immunoassay. *Am. J. Clin. Pathol.* 136, 696–704. doi: 10.1309/AJCP7UBK8IBVMVNR
- Mawuenyega, K. G., Sigurdson, W., Ovod, V., Munsell, L., Kasten, T., Morris, J. C., et al. (2010). Decreased clearance of CNS beta-amyloid in Alzheimer's disease. *Science* 330:1774. doi: 10.1126/science.1197623
- McDonald, C. R., McEvoy, L. K., Gharapetian, L., Fennema-Notestine, C., Hagler, D. J., Holland, D., et al. (2009). Regional rates of neocortical atrophy from normal aging to early Alzheimer disease. *Neurology* 73, 457–465. doi: 10.1212/WNL.0b013e3181b16431



- McGeer, P. L., Itagaki, S., Boyes, B. E., and McGeer, E. G. (1988). Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. *Neurology* 38, 1285–1285.
- McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., et al. (2011). The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimer's Dement.* 7, 263–269. doi: 10.1016/j.jalz.2011.03.005
- Mogi, M., Harada, M., Kondo, T., Riederer, P., Inagaki, H., Minami, M., et al. (1994a). Interleukin-1 $\beta$ , interleukin-6, epidermal growth factor and transforming growth factor- $\alpha$  are elevated in the brain from parkinsonian patients. *Neurosci. Lett.* 180, 147–150. doi: 10.1016/0304-3940(94)90508-8
- Mogi, M., Harada, M., Riederer, P., Narabayashi, H., Fujita, K., and Nagatsu, T. (1994b). Tumor necrosis factor- $\alpha$  (TNF- $\alpha$ ) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. *Neurosci. Lett.* 165, 208–210. doi: 10.1016/0304-3940(94)90746-3
- Moreira, F. T. C., Sale, M. G. F., and Di Lorenzo, M. (2017). Towards timely Alzheimer diagnosis: a self-powered amperometric biosensor for the neurotransmitter acetylcholine. *Biosens. Bioelectron.* 87, 607–614. doi: 10.1016/j.bios.2016.08.104
- Mowry, E. M., Deen, S., Malikova, I., Pelletier, J., Bacchetti, P., and Waubant, E. (2009). The onset location of multiple sclerosis predicts the location of subsequent relapses. *J. Neurol. Neurosurg. Psychiatr.* 80, 400–403. doi: 10.1136/jnnp.2008.157305
- Musunuri, S., Wetterhall, M., Ingelsson, M., Lannfelt, L., Artemenko, K., Bergquist, J., et al. (2014). Quantification of the brain proteome in Alzheimer's disease using multiplexed mass spectrometry. *J. Proteome Res.* 13, 2056–2068. doi: 10.1021/pr401202d
- Novakova, L., Axelsson, M., Khademi, M., Zetterberg, H., Blennow, K., Malmström, C., et al. (2017a). Cerebrospinal fluid biomarkers as a measure of disease activity and treatment efficacy in relapsing-remitting multiple sclerosis. *J. Neurochem.* 141, 296–304. doi: 10.1111/jnc.13881
- Novakova, L., Zetterberg, H., Sundström, P., Axelsson, M., Khademi, M., Gunnarsson, M., et al. (2017b). Monitoring disease activity in multiple sclerosis using serum neurofilament light protein. *Neurology* 89, 2230–2237. doi: 10.1212/WNL.0000000000004683
- Oh, J., Yoo, G., Chang, Y. W., Kim, H. J., Jose, J., Kim, E., et al. (2013). A carbon nanotube metal semiconductor field effect transistor-based biosensor for detection of amyloid-beta in human serum. *Biosens. Bioelectron.* 50, 345–350. doi: 10.1016/j.bios.2013.07.004
- Olsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., et al. (2016). CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. *Lancet Neurol.* 15, 673–684. doi: 10.1016/S1474-4422(16)00070-3
- Opsahl, J. A., Vaudel, M., Gulbrandsen, A., Aasebø, E., Van Pesch, V., Franciotta, D., et al. (2016). Label-free analysis of human cerebrospinal fluid addressing various normalization strategies and revealing protein groups affected by multiple sclerosis. *Proteomics* 16, 1154–1165. doi: 10.1002/pmic.201500284
- Ortiz, G. G., Pacheco-Moisés, F. P., Bitzer-Quintero, O. K., Ramírez-Anguiano, A. C., Flores-Alvarado, L. J., Ramírez-Ramírez, V., et al. (2013). Immunology and oxidative stress in multiple sclerosis: clinical and basic approach. *Clin. Dev. Immunol.* 2013:708659. doi: 10.1155/2013/708659
- Parikh, C. R., and Thiessen-Philbrook, H. (2014). Key concepts and limitations of statistical methods for evaluating biomarkers of kidney disease. *J. Am. Soc. Nephrol.* 25, 1621–1629. doi: 10.1681/ASN.2013121300
- Park, S. J., Song, H. S., Kwon, O. S., Chung, J. H., Lee, S. H., An, J. H., et al. (2014). Human dopamine receptor nanovesicles for gate-potential modulators in high-performance field-effect transistor biosensors. *Sci. Rep.* 4:4342. doi: 10.1038/srep04342
- Pascual, B., Prieto, E., Arbizu, J., Marti-Clement, J. M., Peñuelas, I., Quincoces, G., et al. (2012). Decreased carbon-11-flumazenil binding in early Alzheimer's disease. *Brain* 135, 2817–2825. doi: 10.1093/brain/aw210
- Paterson, R. W., Heywood, W. E., Heslegrave, A. J., Magdalinou, N. K., Andreasson, U., Sirka, E., et al. (2016). A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer's disease pathology. *Transl. Psychiatry* 6:e952. doi: 10.1038/tp.2016.194
- Pires, L. R., Marques, F., Sousa, J. C., Cerqueira, J., and Pinto, I. M. (2016). Nano- and micro-based systems for immunotolerance induction in multiple sclerosis. *Hum. Vaccines Immunother.* 12, 1886–1890. doi: 10.1080/21645515.2016.1138190
- Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkman, J., et al. (2017). Parkinson disease. *Nat. Rev. Dis. Prim.* 3, 1–21. doi: 10.1038/nrdp.2017.13
- Polvikoski, T., Sulkava, R., Haltia, M., Kainulainen, K., Vuorio, A., Verkkoniemi, A., et al. (1995). Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. *N. Engl. J. Med.* 333, 1242–1247. doi: 10.1056/NEJM199511093331902
- Popp, J., Oikonomidi, A., Tautvydaitė, D., Dayon, L., Bacher, M., Migliavacca, E., et al. (2017). Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults. *Brain. Behav. Immun.* 62, 203–211. doi: 10.1016/j.bbi.2017.01.020
- Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., et al. (2015). MDS clinical diagnostic criteria for Parkinson's disease. *Mov. Disord.* 30, 1591–1601. doi: 10.1002/mds.26424
- Prabhakar, S., Piatyszek, R., Cirrito, J. R., Wu, Z. Z., and Li, C. Z. (2012). Microbiosensor for Alzheimer's disease diagnostics: detection of amyloid beta biomarkers. *J. Neurochem.* 122, 374–381. doi: 10.1111/j.1471-4159.2012.07709.x
- Rapini, R., and Marrazza, G. (2017). Electrochemical aptasensors for contaminants detection in food and environment: recent advances. *Bioelectrochemistry* 118, 47–61. doi: 10.1016/j.bioelechem.2017.07.004
- Real-Fernández, F., Passalacqua, I., Peroni, E., Chelli, M., Lolli, F., Papini, A. M., et al. (2012). Glycopeptide-based antibody detection in multiple sclerosis by surface plasmon resonance. *Sensors* 12, 5596–5607. doi: 10.3390/s120505596
- Reich, D. S., Lucchinetti, C. F., and Calabresi, P. A. (2018). Multiple sclerosis. *N. Engl. J. Med.* 378, 169–180. doi: 10.1056/NEJMra1401483
- Rocha, N. P., De Miranda, A. S., and Teixeira, A. L. (2015). Insights into neuroinflammation in Parkinson's disease: from biomarkers to anti-inflammatory based therapies. *Biomed. Res. Int.* 2015:628192. doi: 10.1155/2015/628192
- Rushworth, J. V., Ahmed, A., Griffiths, H. H., Pollock, N. M., Hooper, N. M., and Millner, P. A. (2014). A label-free electrical impedimetric biosensor for the specific detection of Alzheimer's amyloid-beta oligomers. *Biosens. Bioelectron.* 56, 83–90. doi: 10.1016/j.bios.2013.12.036
- Russell, A. C., Šimurina, M., Garcia, M. T., Novokmet, M., and Wang, Y., Rudan, I., et al. (2017). The N-glycosylation of immunoglobulin G as a novel biomarker of Parkinson's disease. *Glycobiology* 27, 501–510. doi: 10.1093/glycob/cwx022
- Schuh, C., Wimmer, I., Hametner, S., Haider, L., Van Dam, A. M., Liblau, R. S., et al. (2014). Oxidative tissue injury in multiple sclerosis is only partly reflected in experimental disease models. *Acta Neuropathol.* 128, 247–266. doi: 10.1007/s00401-014-1263-5
- Sciaccia, B., François, A., Klingler-Hoffmann, M., Brazzatti, J., Penno, M., Hoffmann, P., et al. (2013). Radiative-surface plasmon resonance for the detection of apolipoprotein E in medical diagnostics applications. *Nanomedicine* 9, 550–557. doi: 10.1016/j.nano.2012.10.007
- Song, Y., Chen, P., Chung, M. T., Nidetz, R., Park, Y., Liu, Z., et al. (2017). AC electroosmosis-enhanced nanoplasmo-fluidic detection of ultralow-concentration cytokine. *Nano Lett.* 17, 2374–2380. doi: 10.1021/acs.nanolett.6b05313
- Spellman, D. S., Wildsmith, K. R., Honigberg, L. A., Tuefferd, M., Baker, D., Raghavan, N., et al. (2015). Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF. *Proteomics Clin. Appl.* 9, 715–731. doi: 10.1002/prca.201400178
- Stilund, M., Gjelstrup, M. C., Petersen, T., Møller, H. J., Rasmussen, P. V., and Christensen, T. (2015). Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel. *PLoS ONE* 10:e119681. doi: 10.1371/journal.pone.0119681
- Stumpf, C., Lehner, C., Yilmaz, A., Daniel, W. G., and Garlisch, C. D. (2003). Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in patients with advanced chronic heart failure. *Clin. Sci.* 105, 45–50. doi: 10.1042/CS20020359



- Sulzer, D., Alcalay, R. N., Garretti, F., Cote, L., Kanter, E., Agin-Liebes, J., et al. (2017). T cells from patients with Parkinson's disease recognize  $\alpha$ -synuclein peptides. *Nature* 546, 656–661. doi: 10.1038/nature22815
- Teunissen, C. E., Malekzadeh, A., Leurs, C., Bridel, C., and Killestein, J. (2015). Body fluid biomarkers for multiple sclerosis—the long road to clinical application. *Nat. Rev. Neurol.* 11, 585–596. doi: 10.1038/nrneuro.2015.173
- Thompson, A. J., Banwell, B. L., Barkhof, F., Carroll, W. M., Coetzee, T., Comi, G., et al. (2017). Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. *Lancet Neurol.* 17, 162–173. doi: 10.1016/S1474-4422(17)30470-2
- Vasilescu, A., and Marty, J. L. (2016). Electrochemical aptasensors for the assessment of food quality and safety. *Trends Anal. Chem.* 79, 60–70. doi: 10.1016/j.trac.2015.11.024
- Vilela, P., El-Sagheer, A., Millar, T. M., Brown, T., Muskens, O. L., and Kanaras, A. G. (2017). Graphene oxide-upconversion nanoparticle based optical sensors for targeted detection of mRNA biomarkers present in Alzheimer's disease and prostate cancer. *ACS Sens.* 2, 52–56. doi: 10.1021/acssensors.6b00651
- Wang, S. X., Acha, D., Shah, A. J., Hills, F., Roitt, I., Demosthenous, A., et al. (2017). Detection of the tau protein in human serum by a sensitive four-electrode electrochemical biosensor. *Biosens. Bioelectron.* 92, 482–488. doi: 10.1016/j.bios.2016.10.077
- Wang, W.-Y., Tan, M., Yu, J.-T., and Tan, L. (2015). Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease. *Ann. Transl. Med.* 3, 1–15. doi: 10.3978/j.issn.2305-5839.2015.03.49
- Williams-Gray, C. H., Wijeyekoon, R., Yarnall, A. J., Lawson, R. A., Breen, D. P., Evans, J. R., et al. (2016). Serum immune markers and disease progression in an incident Parkinson's disease cohort (ICICLE-PD). *Mov. Disord.* 31, 995–1003. doi: 10.1002/mds.26563
- Xia, N., Liu, L., Harrington, M. G., Wang, J., and Zhou, F. (2010). Regenerable and simultaneous surface plasmon resonance detection of A beta(1-40) and A beta(1-42) peptides in cerebrospinal fluids with signal amplification by streptavidin conjugated to an n-terminus-specific antibody. *Anal. Chem.* 82, 10151–10157. doi: 10.1021/ac102257m
- Xia, N., Zhou, B., Huang, N., Jiang, M., Zhang, J., and Liu, L. (2016). Visual and fluorescent assays for selective detection of beta-amyloid oligomers based on the inner filter effect of gold nanoparticles on the fluorescence of CdTe quantum dots. *Biosens. Bioelectron.* 85, 625–632. doi: 10.1016/j.bios.2016.05.066
- Xing, Y., Feng, X. Z., Zhang, L., Hou, J., Han, G. C., and Chen, Z. (2017). A sensitive and selective electrochemical biosensor for the determination of beta-amyloid oligomer by inhibiting the peptide-triggered in situ assembly of silver nanoparticles. *Int. J. Nanomedicine* 12, 3171–3179. doi: 10.2147/IJN.S132776
- Yadav, S. K., Mindur, J. E., Ito, K., and Dhib-Jalbut, S. (2015). Advances in the immunopathogenesis of multiple sclerosis. *Curr. Opin. Neurol.* 28, 206–219. doi: 10.1097/WCO.0000000000000205
- Yang, Y., Gu, Y., Wan, B., Ren, X., and Guo, L. H. (2017). Label-free electrochemical biosensing of small-molecule inhibition on O-GlcNAc glycosylation. *Biosens. Bioelectron.* 95, 94–99. doi: 10.1016/j.bios.2017.04.009
- Yildirim, A., and Bayindir, M. (2014). Turn-on fluorescent dopamine sensing based on in situ formation of visible light emitting polydopamine nanoparticles. *Anal. Chem.* 86, 5508–5512. doi: 10.1021/ac500771q
- Yu, S., Liu, Y. P., Liu, Y. H., Jiao, S. S., Liu, L., Wang, Y. J., et al. (2016). Diagnostic utility of VEGF and soluble CD40L levels in serum of Alzheimer's patients. *Clin. Chim. Acta* 453, 154–159. doi: 10.1016/j.cca.2015.12.018
- Yue, H. Y., Huang, S., Chang, J., Heo, C., Yao, F., Adhikari, S., et al. (2014). ZnO nanowire arrays on 3D hierarchical graphene foam: Biomarker detection of parkinson's disease. *ACS Nano* 8, 1639–1646. doi: 10.1021/nn405961p
- Yuzwa, S. A., and Vocadlo, D. J. (2014). O-GlcNAc and neurodegeneration: biochemical mechanisms and potential roles in Alzheimer's disease and beyond. *Chem. Soc. Rev.* 43, 6839–6858. doi: 10.1039/c4cs00038b
- Zetterberg, H. (2017). Fluid biomarkers for microglial activation and axonal injury in multiple sclerosis. *Acta Neurol. Scand.* 136, 15–17. doi: 10.1111/ane.12845
- Zhang, X., Zambrano, A., Lin, Z. T., Xing, Y., Rippey, J., and Wu, T. (2017). Immunosensors for biomarker detection in autoimmune diseases. *Arch. Immunol. Ther. Exp.* 65, 111–121. doi: 10.1007/s00005-016-0419-5
- Zhang, Y., Zhang, B., Ye, X., Yan, Y., Huang, L., Jiang, Z., et al. (2016). Electrochemical immunosensor for interferon- $\gamma$  based on disposable ITO detector and HRP-antibody-conjugated nano gold as signal tag. *Mater. Sci. Eng. C* 59, 577–584. doi: 10.1016/j.msec.2015.10.066
- Zhou, Y., Zhang, H., Liu, L., Li, C., Chang, Z., Zhu, X., et al. (2016). Fabrication of an antibody-aptamer sandwich assay for electrochemical evaluation of levels of  $\beta$ -amyloid oligomers. *Sci. Rep.* 6:35186. doi: 10.1038/srep35186

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2018 Abreu, Soares-dos-Reis, Melo, Relvas, Guimarães, Sá, Cruz and Mendes Pinto. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.